Navigation Links
Arpida Interim Results for six Months to 30 June 2007
Date:8/28/2007

ults

In the first half of 2007, revenues of CHF 0.1 million were generated, related to contract research carried out for third parties.

Total operating expenses increased to CHF 33.7 million for the first six months of 2007.Of these expenses CHF 2.7 million relate to IFRS 2 non-cash charges for options accounting whereas this charge was CHF 1.0 million in the first half of 2006.

In the first half of 2007, 82% of the total operating expenses or CHF 27.7 million (first half of 2006: CHF 23.9 million) was spent on research & development, a substantial part of which was related to the phase III clinical trial programme with intravenous iclaprim.

Management and general expenses were CHF 6.0 million in the first half of 2007 (first half of 2006: CHF 4.6 million), thus remaining at a low level relative to the total operating expenses.

Financial income rose from CHF 0.6 million to CHF 0.8 million. This increase is mainly due to higher levels of cash invested and higher interest rates in Swiss Francs money market accounts. Financial expenses increased to CHF 0.8 million due to unrealised currency translation differences on inter-company relationships and CHF 0.3 million of realised exchange losses. On balance, the net financial result amounts to zero.

Balance sheet / cash flow

Cash and financial investments stood at CHF 94.7 million as per 30 June 2007, an increase of CHF 21.9 million relative to the situation at year-end 2006. The funds are held in current and money market accounts with leading banks.

Cash used in operating activities amounted to CHF 29.8 million (first half of 2006: CHF 24.0 million), while investing activities required CHF 0.9 million, compared with CHF 2.8 million in the first half of 2006. Financing activities amounted to CHF 52.2 million, mainly reflecting the proceeds of the share issue of March 2007.

In the share placing of March 2007, 1.7 million registered common shares from authorised capital w
'/>"/>

SOURCE Arpida
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Effects of Thermal Cycler Well-To-Well Temperature Uniformity on PCR Results
2. HotMasterAn innovative Hot Start/Cold Stop technology for better PCR* results
3. Achieving Reliable Protein Quantitation Results Using ICAT Reagents, MALDITOF Mass Spectrometry, and Advanced Data Interpretation Tool
4. How Best Buy said bye to burnout, hello to results
5. Economic survey reveals better 2006 results
6. Third Wave Reports Third-Quarter Financial Results
7. Tech Digest: Merge eMed product updates; Renaissance Learning 3rd qtr results
8. Midwest small-cap life sciences turn in mixed third-quarter results
9. To boost advertising results, consider improving your web site
10. RedPrairie Reports Strong Results
11. 2003 Biotech Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... 21, 2015  Prima Biomed Ltd. (NASDAQ: PBMD ... to become a leader in the development of immunotherapeutic ... the final CVac data from the Phase II CAN-003 ... for a clinically meaningful improvement in Overall Survival ("OS") ... In the group of second remission patients ...
(Date:5/21/2015)... May 21, 2015  The EveryLife Foundation for ... (R-UT) and Amy Klobuchar (D-MN) today ... Cures & Treatments, or OPEN ACT. ... advocacy organizations, this bipartisan legislation promises to rapidly ... to rare disease patients by incentivizing drug makers ...
(Date:5/21/2015)... May 21, 2015 W. R. ... manufacturing facility in Worms, Germany has received good ... subsidiary of the International Pharmaceutical Excipient Council (IPEC) ... that produce its SYLOID® FP brand of pharmaceutical ... certification, following the Curtis Bay, Maryland (USA) and ...
(Date:5/21/2015)... , May 21, 2015  CytRx Corporation ... development company specializing in oncology, today announced positive ... trial with aldoxorubicin for the treatment of unresectable ... cancer.  The open-label, multisite trial is designed to ... in patients whose tumors have progressed following prior ...
Breaking Biology Technology:Correction Continues after Big Move - BrokerBank Securities, Inc. 2Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7
... , , , ... Choose Shrimp Alkaline Phosphatase,for Easier Heat Inactivation , ... , , Simplify dephosphorylation of 5′ ends ... Shrimp Alkaline Phosphatase completely,and irreversibly by heating at 65 C for only 15 ...
... , , ... , Polymerase chain reaction (PCR) setup typically requires,thawing of ... individual reaction tubes. ,The various handling steps, , , ... , bear the risk of contaminating the amplification,reaction and , ...
... , , Product Literature Center Articles , , ... , , ... Patterns with Improved Tools for Target Amplification , , , ... FastStart Taq DNA Polymerase and the Novel FastStart High Fidelity PCR System , ...
Cached Biology Technology:Reduce Errors and Save Time When Setting Up PCRs 2Roche Diagnostics Corporation 2Roche Diagnostics Corporation 3Roche Diagnostics Corporation 4Roche Diagnostics Corporation 5
(Date:5/11/2015)... -- Curemark LLC, a privately held drug research and ... III double blind, randomized, placebo-controlled clinical trial to examine ... children ages 3-8 with Autism. Previously, Curemark announced the ... clinical trial for CM-AT in children ages 3-8 with ... chymotrypsin. This new trial will help determine whether all ...
(Date:5/6/2015)... 6, 2015 LifeBEAM, a developer of bio-sensing ... announced today that they will expand their partnership in ... bio-sensing cycling helmet and the first joint project between ... colors in order to give cyclists more style choices ... LifeBEAM and Lazer announced their plan to release a ...
(Date:4/27/2015)... Fla. , Apr. 27, 2015 Profile ... access control and security systems is pleased to announce ... company as a consultant and member of its scientific ... is widely known as a thought leader in technology-enhanced ... Learning Technology Group, and has published studies and books ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4
... Researchers at Georgetown University Medical Center have discovered ... on genes that can push stem cells embedded in a ... build blood vessels to link up to the body,s blood ... published in the July 16 online issue of PLoS ...
... Although sickle cell disease is a single-gene disorder, its ... July 14 by the Proceedings of the National ... and the Dana Farber Cancer Institute (DFCI), in collaboration ... five gene variants that could potentially be helpful in ...
... 15, 2008 A new book from the Soil Science Society of ... living world of soil. Soil! Get the Inside Scoop explores how ... the air we breathe, the water we drink, the houses we ... healthy plants and food production. Written for children age 9 to ...
Cached Biology News:Vitamin A pushes breast cancer to form blood vessel cells 2Vitamin A pushes breast cancer to form blood vessel cells 3Gaining ground on sickle cell disease 2Gaining ground on sickle cell disease 3
15(S)-HETE-d8 is used as an internal standard for the quantification of 15(S)-HETE by stable isotope dilution mass spectrometry....
5(S)-HETE-d8 is used as an internal standard for the quantification of 5(S)-HETE by stable isotope dilution mass spectrometry....
...
Full-length cDNA clone CS0DJ013YG01 of T cells (Jurkat cell line) of Homo sapiens (human). [Source:Uniprot/SPTREMBL;Acc:Q86SZ3] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Biology Products: